Blockade of CTLA-4 promotes the development of effector CD8+ T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1
- 18 November 2014
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 64 (3) , 311-323
Abstract
The development of cancer immunotherapy has long been a challenge. Here, we report that prophylactic vaccination with a highly attenuated Trypanosoma cruzi strain expressing NY-ESO-1 (CL-14-NY-ESO-1) induces both effector memory and effector CD8+ T lymphocytes that efficiently prevent tumor development. However, the therapeutic effect of such a vaccine is limited. We also demonstrate that blockade of Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) during vaccination enhances the frequency of NY-ESO-1-specific effector CD8+ T cells producing IFN-γ and promotes lymphocyte migration to the tumor infiltrate. As a result, therapy with CL-14-NY-ESO-1 together with anti-CTLA-4 is highly effective in controlling the development of an established melanoma.Keywords
This publication has 48 references indexed in Scilit:
- Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patientsProceedings of the National Academy of Sciences, 2012
- Trypanosoma cruzias an effective cancer antigen delivery vectorProceedings of the National Academy of Sciences, 2011
- Multiple Cancer/Testis Antigens Are Preferentially Expressed in Hormone-Receptor Negative and High-Grade Breast CancersPLOS ONE, 2011
- Improvement of different vaccine delivery systems for cancer therapyMolecular Cancer, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsProceedings of the National Academy of Sciences, 2010
- CD8+ T cells in Trypanosoma cruzi infectionCurrent Opinion in Immunology, 2009
- Secondary Replicative Function of CD8 + T Cells That Had Developed an Effector PhenotypeScience, 2009
- CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cellsJournal of Clinical Investigation, 2006
- Lineage relationship and protective immunity of memory CD8 T cell subsetsNature Immunology, 2003